Windlas Biotech IPO notes 💊

'What's in a name? that which we call a rose by any other name would smell as sweet' ~Shakespeare

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

1/ Basics about the IPO 👇

Incorporated in 2001

Fresh Issue of 165crs (50 for capex | 48 for Working capital | 20 for debt payment) + OFS of 237crs (Partially by promoter & PE Tano selling out as the fund tenure is up)

~ Total raise of 402crs
2/ About the company (Not a Biotech company)

A Contract manufacturer for formulation cos. (204 in total) for Indian markets & a small domestic OTC biz

3279 products, 4 plants with 700cr tablets/capsules capacity

Emphasis on chronic (60% of rev) & complex generics (70% of rev)
3/ History

FY11 - 100cr 👉 FY14 - 200cr 👉 FY21 - 400cr

Growth is similar to the Indian pharmaceutical sector, not gaining any market share even after increasing products.

Customers include Pfizer, Sanofi India, Eris, Cadila, etc.
4/ Competition: No Moat

400+ organized & 15000 unorganized players in the same space: 2% market share

Some of the things that can drive consolidation: Customers preferring better compliance

However, a single customer usually has 35-40 contract manufacturers for products.
5/ Top competitors

Scale: Players much larger also show a lack of any improvement in metrics.

Remains a low margin & high asset turnover business.
6/ Concentration

Top customer accounts for 11% of rev & Top 10 account for 58%

Interestingly, ramped up number of customers from 97 to 204 in the last 2yrs, however, the concentration remains constant.
7/ R&D

3-4crs spends: at 1% of sales, Increased complex portfolio to 934

Complex generic products have technical complexity in (i) manufacturing or handling of the API; or (ii) formulation; or (iii) route of delivery; or (iv) pairing with a device to make a drug-device combo.
8/ Manufacturing

Utilization at 35-40% currently, can go up to 60-65% before they would have to increase capacity again.
9/ Strategic areas going forward

- Will look for inorganic growth
- Industry to grow at 1.25-1.5x GDP: Increased capacities inline
- To invest 50crs in Injectables facility
- Increase customer base
- Scale-up Domestic OTC & trade generics business
10/ Financials

- Bad Cashflow conversion (20-30% EBITDA) due to huge WC investments
- Low margin business (4-5% net & 10-12% EBITDA & 35% gross margins)
- WC days to stay at 65-75 days
- Asset turnover at 4-5x & can take it to 6-7x
- Rev scaleup needs to be monitored
11/ Risks:

- Dependence on their customers doing well: 90% in B2B business
- Highly competitive, no moat & gruesome business
- Shady dealings with a promoter owned subsidiary: Windlas Healthcare
- No geographical diversification wrt plants.

- Formulations players backwardly integrating their operations: Eris doing the same as it helps them maintain consistent quality & achieve higher margins
- API prices going up (No long term contract with supplier)
- Litigations 👇
- Loss-making Subsidiaries.

At valuations of 2.3x P/S, 19x P/EBITDA & 65x PE, this is valued much higher than most Indian branded formulations are; leaving little to nothing on the table for the investors.

End of Thread.
Industry terms that are mentioned above explained 👇

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ

ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AnishA_Moonka

28 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘Amazon Unbound: Jeff Bezos & the invention of a Global Empire 🏰’ by Brad Stone

This 🧵 will be updated as I read further & further. Image
1/ Quotes to ponder about 👇 Image
2/ The scar tissues. Image
Read 11 tweets
26 Jul
Glenmark Life Sciences (GLS) IPO notes 🔬

Plans to take the capacity to 1762KL (currently 762KL) in the next 4 years.

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

1/ About the company

Developer & manufacturer of high value, non- commoditized APIs (complex & low competition) in chronic therapeutic areas: CVS, CNS, pain management & diabetes, etc

Basic details about the IPO 👇

Note: After paying off liabilities, 150crs remain for capex.
2/ The Journey

Established the API business in FY02

Since 2015, Have not received any adverse reactions from regulators (USFDA, PMDA) in the total 38 audits & inspections & Have gone through 432 customer audits.

Filled 403 DMFs & CEP registration across markets globally.
Read 18 tweets
17 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘The Hidden Life Of Trees: What They Feel, How They Communicate’ by Peter Wolleben (A forester 🌳)

‘Trees in the forest are social beings.’

This thread will be updated as I read further & further.
1/ Trees are underrated.
2/ Wood Wide Web.
Read 22 tweets
15 Jul
Mr. NS Mohan (MD, Suprajit Engineering) gives a perfect example to explain the Indian Automotive Industry: The doll 'Okiagari- Koboshi'

Whenever something hits them, they upright themselves & then again something hits them & on & on. (1/3) Image
Alludes to the fact that been in the industry since 1985 & never seen them being hit with such severity & regularity.

Still, the industry isn't out.

These are the trends that are playing out 👇 (2/30 Image
So what lies ahead? He said: I don't know. (3/3) Image
Read 4 tweets
8 Jul
A thread on the snippets (paragraphs & quotes) from the book ‘Modern Monopolies: What it Takes to Dominate the 21st-Century Economy’

This thread will be updated as I read further & further.
1/ The burning platform.
2/ Why did Nokia fail?
Read 15 tweets
8 Jul
Why your nearby restaurant has a sweet-sour relationship with Zomato/Swiggy?

A mini Thread 🧵👇
1/ Aggregator Economics

Aggregators are cash-guzzling businesses

Although the restaurant volumes go up, increasingly these companies are getting stricter with respect to their cash flows leaving no cut for the restaurant owners

With the listing, this will continue to grow.
2/ Customer Data Masking

Aggregators don't share any user data with the owners leaving them clueless about their customer base, their demographics & trends.

Owners feel that they are losing their brand value & their food is getting commoditized.
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!